In two patients with germline BRCA1 variants, one of whom had breast and the other ovarian cancer, we identified two independent reversion mutations indicative of previously observed polyclonal heterogeneity in tumors treated with platinum therapies and/or PARP inhibitors8. The gene discussed is BRCA1; the disease is ovarian cancer.